Test Program Continues to Meet Sono Motors' Expectations Regarding Crash Safety of the Sion and Robustness of Proprietary Solar Integration
Solar Panels Behave as Predicted: No Splinter and Thus No Additional Risk
Gainers
Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate.